Cancer Therapy Advisor
Reuters
The addition of an experimental Bristol-Myers Squibb biotech medicine to standard therapy for patients whose multiple myeloma has relapsed led to longer remissions and cut the risk of death over standard treatment alone, according to data from a late stage ...
Bristol and AbbVie's Experimental Drug Delayed Blood Cancer Progression ... Wall Street Journal
ASCO '15 -- Bristol, Abbvie Immune-Boosting Drug Lowers Progression Risk in ... TheStreet.com
Elotuzumab Combo Delays Myeloma Progression in Phase III Trial OncLive
Cancer Network
all 6 news articles »
from @ Health and Medical News http://ift.tt/1EDEoeJ
via Health and Medical NewsHealth and Medical News Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal. AstraZeneca turned down a sweeten...
